Human Serum Lot Reservation for IVD Production — How to Calculate and Plan

An IVD manufacturer discovering mid-production that their validated human serum lot has run out is facing a change control event, a comparability study and a potential CE mark update — not just a reorder. Lot reservation planning is not procurement administration. It is risk management. This article shows you how to calculate correctly and manage transitions without production disruption.

Why Lot Changes in Human Serum Are Expensive

Human serum is a biological raw material with inherent lot-to-lot variability. When you validate a lot for use in a CE-marked IVD calibrator or control, that validation is lot-specific — the performance data in your technical file relates to that specific lot number. Switching to a new lot is a raw material change that requires:

• Comparability study: Demonstrate that the new lot produces equivalent assay performance to the validated lot across the full measuring range
• Change control documentation: Record the change in your QMS with justification, risk assessment and corrective actions
• Technical file update: Depending on the significance of the change, this may require notification to your notified body
• Re-release of affected product batches: Any calibrator or control produced with the new lot before comparability completion must be quarantined and re-evaluated

The total cost of a mid-production lot change — including development time, material waste and QMS overhead — typically exceeds €20,000–50,000 for a mid-size IVD manufacturer. The cost of reserving 12 extra months of serum: a fraction of that.

The Reservation Volume Formula

Reservation volume = Annual serum consumption × Project lifecycle (years) × Safety factor 1.5

Key variables to include in "annual consumption":

• Production volume (calibrators/controls manufactured per year × serum per batch)
• QC volume (lot-release testing, stability studies)
• Development reserve (additional batches for formulation optimisation, scale-up)
• Regulatory sample reserve (samples retained for shelf-life and notified body samples)

Managing a Forced Lot Transition Under IVDR

Even with careful planning, forced lot transitions sometimes happen — when a supplier lot expires, supply disruption occurs or quality issues are discovered. When this happens, the comparability study design determines how quickly you can return to production:

Minimum comparability data set

• Side-by-side assay performance comparison across the full measuring range (minimum 5 concentration levels)
• Repeatability study on both lots (minimum 20 replicates per level)
• Bias calculation: new lot vs. reference lot, with pre-defined acceptance criterion (typically ±10% for most quantitative assays)
• Matrix equivalence confirmation: parallelism study with clinical samples diluted in both lots

Timeline expectations

A well-planned comparability study takes 4–8 weeks from initiation to QC release of the new lot. This includes study design, execution, data review, QMS documentation and sample quarantine management. Budget 8–12 weeks if the change requires notified body notification.